Author Archives: clinicalaccelerator

Axon Therapies Announces Positive Early Clinical Data from REBALANCE-HF Randomized Clinical Trial

Below, we are re-publishing with permission the press-release issued by Axon Therapies on May 23, 2022 Late-breaking results presented at the European Society of Cardiology’s Heart Failure Association annual conference and simultaneously published online in the European Journal of Heart … Continue reading

Posted in Cardiology, Central and Eastern Europe, Medical Devices | Leave a comment

Miracor Medical starts 2nd randomized study, targeting expanded indications. 300 patients have been treated with PiCSO®

Below, we are re-publishing with permission the press-release issued by Miracor Medical on March 29, 2022 AWANS, Belgium, March 29, 2022 /PRNewswire/ — Miracor Medical SA (Miracor Medical) today announced the first patient enrolled in the PICSO-AMI-V study to evaluate the benefits … Continue reading

Posted in Cardiology, Medical Devices | Leave a comment

Sequana Medical receives certification under MDR, the new European Medical Device Regulation

Below, we are re-publishing with permission the press-release issued by Sequana Medical on February 14, 2022 alfapump® is one of the first novel Class III active implantable medical devices to be certified Ghent, Belgium – 14 February 2022 – Sequana Medical NV (Euronext … Continue reading

Posted in Biotech | Tagged , , | Leave a comment

Clinical Accelerator announces collaboration with Deerfield Catalyst, a medtech incubator committed to developing transformational solutions to improve patient outcomes and streamline care

Clinical Accelerator, a full-service, medical device focused contract research organization, is pleased to announce a collaboration with Deerfield Catalyst. The company combines the resources of two established health pioneers: Coridea, a New-York based, premier Medical Device Incubator; and Deerfield, an … Continue reading

Posted in Clinical Accelerator, Medical Devices | Leave a comment

Clinical Accelerator announces collaboration with Verve Medical to conduct an early human feasibility study for treatment-resistant hypertension

Clinical Accelerator, a full-service contract research organization, is pleased to announce that it has entered into a collaboration with Verve Medical, to conduct an early human feasibility study of their novel medical device for patients with treatment-resistant hypertension. World-wide, there … Continue reading

Posted in Uncategorized | Leave a comment

ANTERIS REPORTS SUCCESSFUL INTERIM RESULTS FOR THE FIRST-IN-HUMAN TRIAL FOR DurAVR

Below, we are re-publishing with permission the press-release issued by Anteris Technologies Ltd on January 24, 2022 Brisbane, Australia and Minneapolis, USA, Anteris Technologies Ltd (ASX: AVR) reports the first-in-human DurAVR™ THV study met or exceeded its interim study objectives.At … Continue reading

Posted in Cardiology, Medical Devices | Leave a comment

Sequana Medical announces positive interim results of SAHARA DESERT, the alfapump DSR® study in heart failure patients with persistent congestion

Below, we are re-publishing with permission the press-release issued by Sequana Medical NV on December 07, 2021 Interim data from six patients indicate that alfapump DSR therapy can: safely, effectively and rapidly eliminate persistent congestion and restore euvolemia in diuretic-resistant … Continue reading

Posted in Cardiology, Medical Devices | Leave a comment

Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology

DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (NASDAQ: ABMD) announces the successful results of the first-in-human early feasibility study of the preCARDIA system. The preCARDIA system is designed to improve decongestion in acutely decompensated heart failure (ADHF) patients by intermittently occluding the superior vena cava. … Continue reading

Posted in Cardiology, Central and Eastern Europe, Medical Devices | Leave a comment

InterVene’s BlueLeaf Endovenous Valve Formation (EVF) System Granted Breakthrough Device Designation by the FDA

Below, we are re-publishing with permission the press-release issued by InterVene, Inc. on December 13, 2021 December 13, 2021 07:00 AM Eastern Standard Time SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–InterVene Inc. announced today that it has received Breakthrough Device Designation by … Continue reading

Posted in Uncategorized | Leave a comment

AtriAN Medical’s Clinical Data Highlighted at the 2022 AF Symposium

Pioneering cardiac autonomic pulsed field ablation (PFA) technology provides a unique option for enhancing the durability of AF ablation. GALWAY, Ireland, Jan. 17, 2022 /PRNewswire/ — Irish medical device company AtriAN Medical today announced that clinical data from it’s first-in-human study was presented … Continue reading

Posted in Cardiology, Clinical Accelerator, Conferences, Medical Devices | Leave a comment